Relay Therapeutics
RLAY
178 hedge funds and large institutions have $827M invested in Relay Therapeutics in 2024 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 75 increasing their positions, 49 reducing their positions, and 31 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 49
5.36% less ownership
Funds ownership: 100.86% → 95.5% (-5.4%)
6% less funds holding
Funds holding: 189 → 178 (-11)
25% less capital invested
Capital invested by funds: $1.1B → $827M (-$272M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
29% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 31
90% less call options, than puts
Call options by funds: $12K | Put options by funds: $117K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$8.88M |
| 2 |
CC
Casdin Capital
New York
|
+$7M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
+$6.73M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$6.33M |
| 5 |
Millennium Management
New York
|
+$6.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$23.7M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$13.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.6M |
| 4 |
State Street
Boston,
Massachusetts
|
-$12.1M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.9M |
RLAY Hedge Fund Activity: Q2 2024 in Review
178 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q2 2024, worth a combined $827M — down 25% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of RLAY and 22 opened new positions — a net loss of 9 holders — while 49 trimmed existing stakes and 75 added.
The largest buyer was Logos Global Management, opening a new position worth an estimated $8.88M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $23.7M.
- 178 institutional investors held Relay Therapeutics (RLAY) as of Q2 2024, down from 189 in Q1 2024.
- Funds reported $827M of Relay Therapeutics stock for Q2 2024, down 25% quarter-over-quarter.
- 22 funds opened new Relay Therapeutics positions in Q2 2024 and 31 closed out, a net change of -9 holders.
- The largest Relay Therapeutics buyer in Q2 2024 was Logos Global Management, an estimated $8.88M added.
- The largest Relay Therapeutics seller in Q2 2024 was ArrowMark Colorado Holdings, an estimated $23.7M sold.
Based on aggregated 13F filings for Q2 2024.